Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2014

View Archived Issues

Ebola virus evades the STAT1-mediated immune response

Novel EZH2 inhibitors for diffuse large B-cell lymphoma identified at Pfizer

Isis Pharmaceuticals designs new huntingtin ASOs

Novartis divulges new anti-IL-17A MAbs

German researchers disclose new MAGE A1-recognizing constructs

Discovery of antibacterial compounds with promising activity against Gram-positive pathogens

Novel LXR agonists for the treatment of lipoprotein disorders

INSERM reports new polypeptides for mitochondrial disorders

Swedish group patents new deuterated catecholamine derivatives

DMC recommends initiation of Ruthigen's phase I/II study of RUT-58-60

Patrys plans phase Ib/II study of PAT-SM6 with carfilzomib in multiple myeloma

Pfizer and Merck & Co. to evaluate combination of pembrolizumab and crizotinib

Alkermes initiates phase I trial of the opioid modulator ALKS-7106

NIH supports Sorrento Therapeutics' development of immunotherapy for IPF

BeiGene moves BTK inhibitor BGB-3111 into the clinic

FDA approves Promacta for severe aplastic anemia

Identification of TLR agonists as novel markers for SSc

Innate Pharma's IPH-4102 receives E.U. orphan drug status for cutaneous T-cell lymphoma

EMA accepts for review Cubist's MAA for ceftolozane/tazobactam

Vivolux plans phase I study of VLX-600 for refractory advanced solid tumors

Empagliflozin launched in the U.S. for type 2 diabetes

Adocia launches phase III study of BioChaperone PDGF-BB in diabetic foot ulcers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...